Panitumumab Pivotal Study Shows Increase In Progression-Free Survival

Amgen/Abgenix say twelve-month survival data will be released by second quarter. Rolling BLA submission will begin by year-end, wrapping up in early 2006.

More from Archive

More from Pink Sheet